Immunization therapy in Alzheimer's disease

References

• Cummings JL. Alzheimer's disease. N. Engl. J. Med.351, 56–67 (2004).
   PubMed Web of Science ®Google Scholar
• Takeda A, Loveman E, Clegg A et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int. J. Geriatr. Psychiatry21, 17–28 (2006).
   PubMed Web of Science ®Google Scholar
• Winblad B, Jelic V. Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis. Assoc. Disord.18(Suppl. 1), S2–S8 (2004).
   PubMed Web of Science ®Google Scholar
• Schneider LS, Katz IR, Park S, Napolitano J, Martinez RA, Azen SP. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. Am. J. Geriatr. Psychiatry11, 414–425 (2003).
   PubMedGoogle Scholar
• Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev.81, 741–766 (2001).
   PubMed Web of Science ®Google Scholar
• Sela M, Teitelbaum, D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin.Pharmacother.2, 1149–1165 (2001).
   PubMedGoogle Scholar
• Games D, Adams D, Alessandrini R et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature373, 523–527 (1995).
   PubMed Web of Science ®Google Scholar
• Hsiao K, Chapman P, Nilsen S et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science274, 99–102 (1996).
   PubMed Web of Science ®Google Scholar
• Johnson-Wood K, Lee M, Motter R et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl Acad. Sci. USA94, 1550–1555 (1997).
   PubMed Web of Science ®Google Scholar
• Mucke L, Masliah E, Yu GQ et al. High-level neuronal expression of Aβ 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci.20, 4050–4058 (2000).
   PubMedGoogle Scholar
• Holcomb L, Gordon MN, McGowan E et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med.4, 97–100 (1998).
   PubMed Web of Science ®Google Scholar
• Dineley KT, Xia X, Bui D, Sweatt JD, Zheng H. Accelerated plaque accumulation, associative learning deficits, and up-regulation of α 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem.277, 22768–22780 (2002).
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature400, 173–177 (1999).
   PubMed Web of Science ®Google Scholar
• Janus C, Pearson J, McLaurin J et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature408, 979–982 (2000).
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature408, 982–985 (2000).
   PubMed Web of Science ®Google Scholar
• Younkin SG. Amyloid β vaccination: reduced plaques and improved cognition. Nat. Med.7, 18–19 (2001).
   PubMed Web of Science ®Google Scholar
• Klyubin I, Walsh DM, Lemere CA et al. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nat. Med.11, 556–561 (2005).
   PubMed Web of Science ®Google Scholar
• Bard F., Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med.6, 916–919 (2000).
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Boncristiano S, Bondolfi L et al. Cerebral hemorrhage After passive anti-Aβ immunotherapy. Science298, 1379 (2002).
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Rojiani A, Rosenthal A et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci.24, 6144–6151 (2004).
   PubMed Web of Science ®Google Scholar
• Lemere CA, Beierschmitt A, Iglesias M et al. Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean vervet. Am. J. Pathol.165, 283–297 (2004).
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA98, 8850–8855 (2001).
   PubMed Web of Science ®Google Scholar
• Lemere CA, Spooner ET, Lafrancois J et al. Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice. Neurobiol.Dis.14, 10–18 (2003).
   PubMed Web of Science ®Google Scholar
• Deane R., Sagare A, Hamm K et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood–brain barrier neonatal Fc receptor. J. Neurosci.25, 11495–11503 (2005).
   PubMed Web of Science ®Google Scholar
• Dodart JC, Bales KR, Gannon KS et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci.5, 452–457 (2002).
   PubMed Web of Science ®Google Scholar
• Frenkel D, Kariv N, Solomon B. Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine19, 2615–2619 (2001).
   PubMed Web of Science ®Google Scholar
• Solomon B. Generation of anti-β-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination. Vaccine23, 2327–2330 (2005).
   PubMedGoogle Scholar
• Lavie V, Becker M, Cohen-Kupiec R et al. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J. Mol. Neurosci.24, 105–113 (2004).
   PubMed Web of Science ®Google Scholar
• Bard F, Barbour R, Cannon C et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl Acad. Sci. USA100, 2023–2028 (2003).
   PubMed Web of Science ®Google Scholar
• Mor F, Quintana F, Mimran A, Cohen IR. Autoimmune encephalomyelitis and uveitis induced by T cell immunity to self β-synuclein. J. Immunol.170, 628–634 (2003).
   PubMedGoogle Scholar
• Furlan R, Brambilla E, Sanvito F et al. Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain126, 285–291 (2003).
   PubMed Web of Science ®Google Scholar
• Das P, Chapoval S, Howard V, David CS, Golde TE. Immune responses against Aβ1–42 in HLA class II transgenic mice: implications for Aβ1–42 immune-mediated therapies. Neurobiol. Aging24, 969–976 (2003).
   PubMedGoogle Scholar
• Spooner ET, Desai RV, Mori C, Leverone JF, Lemere CA. The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol. Vaccine21, 290–297 (2002).
   PubMedGoogle Scholar
• Lee EB, Leng LZ, Lee VM, Trojanowski JQ. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett.579, 2564–2568 (2005).
   PubMed Web of Science ®Google Scholar
• Monsonego A, Imitola J, Petrovic S et al. Aβ-induced meningoencephalitis is IFN-{γ}-dependent and is associated with T cell-dependent clearance of Aβ in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA103, 5048–5053 (2006).
   PubMed Web of Science ®Google Scholar
• Monsonego A, Zota V, Karni A et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J. Clin. Invest.112, 415–422 (2003).
   PubMed Web of Science ®Google Scholar
• Qu B, Rosenberg RN, Li L, Boyer PJ, Johnston SA. Gene vaccination to bias the immune response to amyloid-β peptide as therapy for Alzheimer disease. Arch. Neurol.61, 1859–1864 (2004).
   PubMedGoogle Scholar
• Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL. Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl Acad. Sci. USA98, 10273–10278 (2001).
   PubMedGoogle Scholar
• Agadjanyan MG, Ghochikyan A, Petrushina I et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol.174, 1580–1586 (2005).
   PubMed Web of Science ®Google Scholar
• Aharoni R, Arnon R, EilamR. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurosci.25, 8217–8228 (2005).
   PubMed Web of Science ®Google Scholar
• Weiner HL, Lemere CA, Maron R et al. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol.48, 567–579 (2000).
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T, Lin C, Yan F et al. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat. Med.7, 612–618 (2001).
   PubMed Web of Science ®Google Scholar
• Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M. Activation of microglia by aggregated β-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-γ and IL-4 render them protective. Mol. Cell Neurosci.29, 381–393 (2005).
   PubMedGoogle Scholar
• Butovsky O, Ziv Y, Schwartz A et al. Microglia activated by IL-4 or IFN-γ differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol. Cell Neurosci. 31(1), 149–149 (2006).
   PubMed Web of Science ®Google Scholar
• Frenkel D, Maron R, Burt DS, Weiner HL. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest.115, 2423–2433 (2005).
   PubMedGoogle Scholar
• Monsonego A, Imitola J, Zota V, Oida T, Weiner HL. Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid β-peptide presentation to Th1 cells. J. Immunol.171, 2216–2224 (2003).
   PubMed Web of Science ®Google Scholar
• Racke MM, Boone LI, Hepburn DL et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β. J. Neurosci.25, 629–636 (2005).
   PubMed Web of Science ®Google Scholar
• Burbach GJ, Vlachos A, Ghebremedhin E et al. Vessel ultrastructure in APP23 transgenic mice after passive anti-Aβ immunotherapy and subsequent intracerebral hemorrhage. Neurobiol. Aging (2006) [Epub ahead of print].
   PubMedGoogle Scholar
• Chauhan NB, Siegel GJ. Efficacy of anti-Aβ antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosci. Lett.375, 143–147 (2005).
   PubMedGoogle Scholar
• Levites Y, Das P, Price RW et al. Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest.116, 193–201 (2006).
   PubMed Web of Science ®Google Scholar
• Gandy S, Walker L. Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-β vaccination in nonhuman primates. Curr. Opin. Immunol.16, 607–615 (2004).
   PubMed Web of Science ®Google Scholar
• Bayer AJ, Bullock R, Jones RW et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology64, 94–101 (2005).
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with AD After Aβ42 immunization. Neurology61, 46–54 (2003).
   PubMed Web of Science ®Google Scholar
• Masliah E, Hansen L, Adame Aet al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology64, 129–131 (2005).
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med.9, 448–452 (2003).
   PubMed Web of Science ®Google Scholar
• Greenberg SM, Bacskai BJ, Hyman BT. Alzheimer disease's double-edged vaccine. Nat. Med.9, 389–390 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol.14, 11–20 (2004).
   PubMed Web of Science ®Google Scholar
• Hock C, Konietzko U, Streffer JR et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron38, 547–554 (2003).
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology64, 1553–1562 (2005).
   PubMed Web of Science ®Google Scholar
• Fox NC, Black RS, Gilman Set al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology64, 1563–1572 (2005).
   PubMed Web of Science ®Google Scholar
• Dodel RC, Du Y, Depboylu C et al. Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry75, 1472–1474 (2004).
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol.159, 439–447 (2001).
   PubMed Web of Science ®Google Scholar
• Cribbs DH, Ghochikyan A, Vasilevko V et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid. Int. Immunol.15, 505–514 (2003).
   PubMed Web of Science ®Google Scholar
• Maier M, Seabrook TJ, Lemere CA. Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). Vaccine23, 5149–5159 (2005).
   PubMed Web of Science ®Google Scholar
• Hara H, Monsonego A, Yuasa K et al. Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J. Alzheimers Dis.6, 483–488 (2004).
   PubMed Web of Science ®Google Scholar
• Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc. Natl Acad. Sci. USA97, 11455–11459 (2000).
   PubMed Web of Science ®Google Scholar
• McLaurin J, Cecal R, Kierstead ME et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med.8, 1263–1269 (2002).
   Google Scholar
• Kim HJ, Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin. Immunol.104, 105–114 (2002).
   PubMed Web of Science ®Google Scholar